Stock Market Stories and Insights

<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#000000;color: #f2f2f2;font-size:1.1em;;'>SC</div>
  over two weeks ago at Macroaxis 
By Ellen Johnson
In general, we focus on analyzing Studio (NYSE:MSC) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Studio City International daily price indicators and compare them against related drivers. In this post we will go over Studio City. Why are we still confident in our hopes for a recovery.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;;'>SIN</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
As many investors are getting excited about communication services space, it is fair to go over Sina Corporation. We will check if it is still possible for Sina to minimize net losses this year. In this post, I will also go over some essential variables affecting Sina's products, and show how it may impact Sina outlook for active traders this year.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;;'>SIN</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
While some baby boomers are getting worried about communication services space, it is reasonable to go over Sina Corporation. Why are we still confident in hope for a quick recovery. Here I will also expose some primary fundamental factors affecting Sina's services, and outline how it will impact the outlook for investors this year.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#9CBEFD;color: #ffffff;font-size:1.1em;;'>NI</div>
  over two weeks ago at Macroaxis 
By Vlad Skutelnik
NanoViricides NEW is scheduled to announce its earnings tomorrow. The stock is undergoing a sell-off trend. NanoViricides Inc Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 18.36 Million. The current year Average Equity is expected to grow to about 17.6 M, whereas Net Income Per Employee is forecasted to decline to (1.8 M). As many investors are getting excited about healthcare space, it is fair to go over NanoViricides Inc NEW as an investment option.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;;'>PE</div>
  over two weeks ago at Macroaxis 
By Achuva Shats
As many millenniums are trying to avoid energy space, it makes sense to review Peabody Energy a little further and try to understand its current market patterns. As expected, Peabody Energy is starting to reaffirm its true potential as private investors are becoming more and more confident in the future outlook. The returns on the market and returns on Peabody Energy appear slightly related to each other for the last few months. Uncertain basic indicators of the firm may also call for signs of mid-term losses for Peabody private investors. The upcoming quarterly report is expected on the 3rd of February 2021. The stock is currently undergoing an active upward rally.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#169D0B;color: #E6E6FA;font-size:1.1em;;'>AC</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
The stock experiences an active upward rally. AeroCentury Corp EBITDA Margin is fairly stable at the moment as compared to the past year. AeroCentury Corp reported EBITDA Margin of 0.036 in 2020. Enterprise Value over EBITDA is likely to rise to 88.57 in 2021, whereas Earnings before Tax are likely to drop (19.6 M) in 2021. As many millenniums are trying to avoid industrials space, it makes sense to break down AeroCentury Corp a little further and try to understand its current market patterns. What exactly are AeroCentury Corp shareholders getting in February?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;;'>BG</div>
  over two weeks ago at Macroaxis 
By Vlad Skutelnik
Bionano Genomics Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 0.30. Current Ratio is expected to rise to 1.76 this year, although the value of Average Assets will most likely fall to about 26.6 M. My story will outline Bionano Genomics. We will cover the possibilities of making Bionano Genomics into a steady grower in February. This post is to show some fundamental factors affecting Bionano Genomics' products and services. I will also disclose how it may impact the investing outlook for the company in February.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;;'>GS</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
The stock is still going through an active upward rally. While some baby boomers are getting worried about basic materials space, it is reasonable to outline Gatos Silver as an investment alternative. Here we also measure the ability of Gatos Silver to meet its long-term debt obligations, such as interest payments on debt, the final principal payment on the debt, and any other fixed obligations like lease payments.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;;'>EP</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
The upcoming quarterly report is expected on the 4th of March 2021. The stock just had it stock split. EyePoint Pharmaceuticals has reported 1 for 10 split on 9th of December 2020. EyePoint Pharmaceuticals Price to Book Value is comparatively stable at the moment as compared to the past year. EyePoint Pharmaceuticals reported Price to Book Value of 23.14 in 2020. Price to Sales Ratio is likely to gain to 9.37 in 2021, whereas Free Cash Flow is likely to drop (52.6 M) in 2021. While some baby boomers are getting worried about healthcare space, it is reasonable to review EyePoint Pharmaceuticals as an investment alternative. What exactly are EyePoint Pharmaceuticals shareholders getting in February?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;;'>SIN</div>
  over two weeks ago at Macroaxis 
By Achuva Shats
While many traders are getting carried away by overanalyzing communication services space, it is reasonable to go over Sina Corporation. Why are we still confident in hope for a quick recovery. This post is to show some fundamental factors affecting Sina's products and services. I will also drop some light on how it may impact the investing outlook for Sina in February.